Ceti TAD may be available in the countries listed below.
Cetirizine dihydrochloride (a derivative of Cetirizine) is reported as an ingredient of Ceti TAD in the following countries:
International Drug Name Search
Polyvidone may be available in the countries listed below.
Polyvidone (DCF) is known as Povidone in the US.
International Drug Name Search
Glossary
| DCF | Dénomination Commune Française |
Stibatin may be available in the countries listed below.
Sodium Stibogluconate is reported as an ingredient of Stibatin in the following countries:
International Drug Name Search
Nonflamin may be available in the countries listed below.
Tinoridine hydrochloride (a derivative of Tinoridine) is reported as an ingredient of Nonflamin in the following countries:
International Drug Name Search
Carduran CR may be available in the countries listed below.
Doxazosin mesilate (a derivative of Doxazosin) is reported as an ingredient of Carduran CR in the following countries:
International Drug Name Search
Felden-Quick-Solve may be available in the countries listed below.
Piroxicam is reported as an ingredient of Felden-Quick-Solve in the following countries:
International Drug Name Search
Generic Name: risedronate (rih SED ro nayt)
Brand Names: Actonel, Atelvia
Risedronate is in a group of medicines called bisphosphonates (bis FOS fo nayts). It alters the cycle of bone formation and breakdown in the body. Risedronate slows bone loss while increasing bone mass, which may prevent bone fractures.
Risedronate is used to treat or prevent osteoporosis in men and women. Risedronate is also used to treat Paget's disease of bone.
Risedronate may also be used for purposes not listed in this medication guide.
Do not take a risedronate tablet if you cannot sit upright or stand for at least 30 minutes. Risedronate can cause serious problems in the stomach or esophagus (the tube that connects your mouth and stomach). You will need to stay upright for at least 30 minutes after taking this medication.
Take the Actonel tablet first thing in the morning with a full glass (6 to 8 ounces) of water, at least 30 minutes before you eat or drink anything or take any other medicine.
Take the Atelvia tablet just after breakfast, with at least 4 ounces of water.
For at least the first 30 minutes after taking a risedronate tablet, do not lie down or recline; do not eat or drink anything other than plain water; and do not take any other medicines including vitamins, calcium, or antacids.
Some people using medicines similar to risedronate have developed bone loss in the jaw, also called osteonecrosis of the jaw. Symptoms of this condition may include jaw pain, swelling, numbness, loose teeth, gum infection, or slow healing after injury or surgery involving the gums. You may be more likely to develop osteonecrosis of the jaw if you have cancer or have been treated with chemotherapy, radiation, or steroids. Other conditions associated with osteonecrosis of the jaw include blood clotting disorders, anemia (low red blood cells), and pre-existing dental problems.
Talk with your doctor about the risks and benefits of using this medication.
To make sure you can safely take risedronate, tell your doctor if you have any of these other conditions:
low blood calcium (hypocalcemia);
a vitamin D deficiency;
kidney disease; or
an ulcer in your stomach or esophagus.
Some people using medicines similar to risedronate have developed bone loss in the jaw, also called osteonecrosis of the jaw. Symptoms of this condition may include jaw pain, swelling, numbness, loose teeth, gum infection, or slow healing after injury or surgery involving the gums.
You may be more likely to develop osteonecrosis of the jaw if you have cancer or have been treated with chemotherapy, radiation, or steroids. Other conditions associated with osteonecrosis of the jaw include blood clotting disorders, anemia (low red blood cells), and dental surgery or pre-existing dental problems.
Talk with your doctor about the risks and benefits of using this medication.
Take exactly as prescribed by your doctor. Do not take in larger or smaller amounts or for longer than recommended. Follow the directions on your prescription label.
Risedronate tablets come in different strengths (number of milligrams per pill). Some tablets are taken once each day. Some tablets are taken once each week, or only 1 or 2 times each month.
Take the Actonel tablet first thing in the morning with a full glass (6 to 8 ounces) of water, at least 30 minutes before you eat or drink anything or take any other medicine.
Take the Atelvia tablet just after breakfast, with at least 4 ounces of water.
After taking a risedronate tablet, carefully follow these instructions:
Do not lie down or recline for at least 30 minutes after taking risedronate.
Do not eat or drink anything other than plain water.
Do not take any other medicines including vitamins, calcium, or antacids for at least 30 minutes after taking risedronate. It may be best to take your other medicines at a different time of the day. Talk with your doctor about the best dosing schedule for your other medicines.
If you take risedronate only once a week, take it on the same day and time each week.
To be sure this medication is helping your condition, your bone mineral density will need to be tested on a regular basis. Visit your doctor regularly.
Risedronate is only part of a complete program of treatment that may also include diet changes, exercise, and taking calcium and vitamin supplements. Follow your diet, medication, and exercise routines very closely.
See also: Risedronate dosage (in more detail)
If you take risedronate tablets once daily: If you forget to take this medicine first thing in the morning, do not take it later in the day. Wait until the following morning to take the medicine and skip the missed dose. Do not take two (2) tablets in one day.
If you take risedronate tablets once a week, or once or twice per month: If you forget to take risedronate on your scheduled day, take it first thing in the morning on the day after you remember the missed dose. Then return to your regular weekly schedule on your chosen dose day. Do not take two (2) tablets in one day.
Overdose symptoms may include nausea, heartburn, stomach pain, diarrhea, muscle cramps, numbness or tingling, tight muscles in your face, seizure (convulsions), irritability, and unusual thoughts or behavior.
Avoid taking any other medicines including vitamins, calcium, or antacids for at least 30 minutes after taking a risedronate tablet. Some medicines can make it harder for your body to absorb risedronate.
chest pain;
difficulty or pain when swallowing;
pain or burning under the ribs or in the back;
new or worsening heartburn;
severe or ongoing indigestion;
severe joint, bone, or muscle pain;
new or unusual pain in your thigh or hip; or
jaw pain, numbness, or swelling.
Less serious side effects may include:
flu symptoms, muscle pain;
mild stomach pain or upset stomach;
diarrhea, constipation;
mild joint or back pain; or
headache.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1 800 FDA 1088.
Usual Adult Dose for Paget's Disease:
30 mg orally once a day. Therapy should be continued for 2 months. A drug free interval of at least 2 months should be allowed to assess response. Retreatment may be considered after a 2 month period for patients who have relapsed or did not respond based on a failure to normalize serum alkaline phosphatase levels. Data are not available regarding more than one course of treatment.
Usual Adult Dose for Osteoporosis:
For prevention or treatment of postmenopausal osteoporosis: 5 mg orally once daily or 35 mg orally once a week. Also, risedronate 75 mg may be given orally once a day on two consecutive days, for a total of two tablets monthly. Additionally, risedronate 150 mg may be given orally once a month.
For treatment of osteoporosis in men: 35 mg orally once a week.
For prevention or treatment of glucocorticoid induced osteoporosis: 5 mg orally once daily.
Patients should receive adequate supplements of calcium and vitamin D.
Patients should be instructed that if they miss a dose of risedronate 35 mg once a week, they should take 1 tablet on the morning after they remember and return to taking 1 tablet once a week, as originally scheduled on their chosen day. Patients should not take 2 tablets on the same day.
If one or both tablets of risedronate 75 mg on two consecutive days/month are missed, and the next month's scheduled doses are more than 7 days away, the patient should be instructed as follows: If both tablets are missed, take one risedronate 75 mg tablet in the morning after the day it is remembered and then the other tablet on the next consecutive morning; if only one risedronate 75 mg tablet is missed, take the missed tablet in the morning after the day it is remembered. Patients should then return to taking their risedronate 75 mg on two consecutive days/month as originally scheduled. Patients should not take more than two 75 mg tablets within 7 days. If one or both tablets of risedronate 75 mg on two consecutive days/month are missed, and the next month's scheduled doses are within 7 days, patients should wait until their next month's scheduled doses and then continue taking risedronate 75 mg on two consecutive days/month as originally scheduled.
If the dose of risedronate 150 mg once a month is missed, and the next month's scheduled dose is more than 7 days away, the patient should be instructed to take the missed tablet in the morning after the day it is remembered. Patients should then return to taking their risedronate 150 mg once a month as originally scheduled. Patients should not take more than one 150 mg tablet within 7 days. If the dose of risedronate 150 mg once a month is missed, and the next month's scheduled dose is within 7 days, patients should wait until their next month's scheduled dose and then continue taking risedronate 150 mg once a month as originally scheduled.
Usual Adult Dose for Prevention of Osteoporosis:
For prevention or treatment of postmenopausal osteoporosis: 5 mg orally once daily or 35 mg orally once a week. Also, risedronate 75 mg may be given orally once a day on two consecutive days, for a total of two tablets monthly. Additionally, risedronate 150 mg may be given orally once a month.
For treatment of osteoporosis in men: 35 mg orally once a week.
For prevention or treatment of glucocorticoid induced osteoporosis: 5 mg orally once daily.
Patients should receive adequate supplements of calcium and vitamin D.
Patients should be instructed that if they miss a dose of risedronate 35 mg once a week, they should take 1 tablet on the morning after they remember and return to taking 1 tablet once a week, as originally scheduled on their chosen day. Patients should not take 2 tablets on the same day.
If one or both tablets of risedronate 75 mg on two consecutive days/month are missed, and the next month's scheduled doses are more than 7 days away, the patient should be instructed as follows: If both tablets are missed, take one risedronate 75 mg tablet in the morning after the day it is remembered and then the other tablet on the next consecutive morning; if only one risedronate 75 mg tablet is missed, take the missed tablet in the morning after the day it is remembered. Patients should then return to taking their risedronate 75 mg on two consecutive days/month as originally scheduled. Patients should not take more than two 75 mg tablets within 7 days. If one or both tablets of risedronate 75 mg on two consecutive days/month are missed, and the next month's scheduled doses are within 7 days, patients should wait until their next month's scheduled doses and then continue taking risedronate 75 mg on two consecutive days/month as originally scheduled.
If the dose of risedronate 150 mg once a month is missed, and the next month's scheduled dose is more than 7 days away, the patient should be instructed to take the missed tablet in the morning after the day it is remembered. Patients should then return to taking their risedronate 150 mg once a month as originally scheduled. Patients should not take more than one 150 mg tablet within 7 days. If the dose of risedronate 150 mg once a month is missed, and the next month's scheduled dose is within 7 days, patients should wait until their next month's scheduled dose and then continue taking risedronate 150 mg once a month as originally scheduled.
Before using risedronate, tell your doctor if you also use aspirin or other NSAIDs (non-steroidal anti-inflammatory drugs) such as celecoxib (Celebrex), diclofenac (Voltaren), diflunisal (Dolobid), ibuprofen (Motrin, Advil), indomethacin, ketoprofen (Orudis), ketorolac (Toradol), naproxen (Aleve, Naprosyn), piroxicam (Feldene), and others.
This list is not complete and other drugs may interact with risedronate. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.
See also: risedronate side effects (in more detail)
Cipasid may be available in the countries listed below.
Cisapride is reported as an ingredient of Cipasid in the following countries:
International Drug Name Search
Endo-Paractol may be available in the countries listed below.
Simeticone is reported as an ingredient of Endo-Paractol in the following countries:
International Drug Name Search
Treating moderate to severe pain. It may be used before surgery to cause sedation and reduce anxiety. It may also be used for other conditions as determined by your doctor.
Oxymorphone Suppositories are a narcotic pain reliever. It works by dulling the pain perception center in the brain. It may also affect other body systems (eg, respiratory and circulatory systems) at higher doses.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with Oxymorphone Suppositories. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Oxymorphone Suppositories. Tell your health care provider if you are taking any other medicines, especially any of the following:
This may not be a complete list of all interactions that may occur. Ask your health care provider if Oxymorphone Suppositories may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Oxymorphone Suppositories as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Oxymorphone Suppositories.
When used for long periods of time or at high doses, Oxymorphone Suppositories may not work as well and may require higher doses to obtain the same effect as when originally taken. This is known as TOLERANCE. Talk with your doctor if Oxymorphone Suppositories stops working well. Do not take more than prescribed.
When used for long periods of time or at high doses, some people develop a need to continue taking Oxymorphone Suppositories. This is known as DEPENDENCE or addiction.
If you suddenly stop taking Oxymorphone Suppositories, you may experience WITHDRAWAL symptoms including anxiety; diarrhea; fever, runny nose, or sneezing; goose bumps and abnormal skin sensations; hallucinations; nausea; vomiting; pain; rigid muscles; rapid heartbeat; shivering or tremors; sweating; and trouble sleeping.
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Constipation; dizziness; drowsiness; headache; nausea; sleeplessness; vomiting; weakness.
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); confusion; difficulty urinating; fast or slow heartbeat; seizures; severe dizziness, lightheadedness, or fainting; slowed or difficult breathing; stomach pain; tremor; vision changes.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
See also: Oxymorphone side effects (in more detail)
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include cold and clammy skin; confusion; loss of consciousness; seizures; severe drowsiness, dizziness, or lightheadedness; slow breathing; slow heartbeat.
Store Oxymorphone Suppositories in the refrigerator, between 36 and 46 degrees F (2 and 8 degrees C). Do not freeze. Do not store in the bathroom. Keep Oxymorphone Suppositories out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about Oxymorphone Suppositories. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Di-Fedril may be available in the countries listed below.
Diphenhydramine hydrochloride (a derivative of Diphenhydramine) is reported as an ingredient of Di-Fedril in the following countries:
International Drug Name Search
Zaso may be available in the countries listed below.
Zaleplon is reported as an ingredient of Zaso in the following countries:
International Drug Name Search
In the US, Mentax (butenafine topical) is a member of the drug class topical antifungals and is used to treat Tinea Corporis, Tinea Cruris and Tinea Pedis.
US matches:
Butenafine hydrochloride (a derivative of Butenafine) is reported as an ingredient of Mentax in the following countries:
International Drug Name Search
Carnon may be available in the countries listed below.
Levocarnitine is reported as an ingredient of Carnon in the following countries:
Ubidecarenone is reported as an ingredient of Carnon in the following countries:
International Drug Name Search
Amebismo may be available in the countries listed below.
Bismuth Subsalicylate is reported as an ingredient of Amebismo in the following countries:
International Drug Name Search
